Sales and Marketing

Showing 15 posts of 11528 posts found.

a_scientist_at_work_at_sanofis_immunology_laboratory_in_thailand

EMA accepts MMA for rheumatoid arthritis treatment Sarilumab

August 1, 2016 Research and Development, Sales and Marketing EMA, MAA, Regeneron, Sanofi, sarilumab

Sanofi and Regeneron Pharmaceuticals have announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for …
GSK image

GSK and Alphabet to create bioelectronics medicines in £540 million partnership

August 1, 2016 Research and Development, Sales and Marketing Alphabet, GSK, Verily, bioelectronic medicine, galvani, google

GlaxoSmithKline and Verily Life Sciences, a division of Google’s parent company Alphabet, have announced a £540 million partnership that will …
humacao_exterior

Bristol-Myers Squibb grows revenues 17% to $4.9 billion in Q2 2016

July 29, 2016 Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, finance, opdivo

Bristol-Myers Squibb has announced its financial results for the second quarter of 2016, noting sizeable year-on-year sales growth and leaps …

China’s Fosun seals $1.3 billion deal for Gland Pharma

July 29, 2016 Medical Communications, Sales and Marketing acquisition, fosun, gland, takeover

Fosun Pharmaceutical has agreed a deal to purchase an 86.1% stake of Gland Pharma, which will see the Chinese firm …
roche_close

Roche urges reform of Cancer Drugs Fund as NICE takes control

July 29, 2016 Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE, Roche

Roche has warned that cancer patients in England are facing into an “uncertain future” as the new Cancer Drugs Fund …

Ashfield provides clarity on the age old debate: ‘Syndicated’ or ‘Dedicated’ field sales?

July 28, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Ashfield is understandably well placed to offer a balanced viewpoint on field sales teams. With over 20 years of experience, …
astrazeneca_building_white

Cholesterol drugs drag AstraZeneca’s profits down in latest financial results

July 28, 2016 Research and Development, Sales and Marketing 2016, AstraZeneca, Q2, h1, results

AstraZeneca has maintained its financial outlook for 2016, despite its Q2 and H1 results showing sharp falls in core earnings …
sanofi_hq__boetie_hall

Sanofi gets FDA approval for type-2 diabetes treatment Adlyxin

July 28, 2016 Research and Development, Sales and Marketing FDA, Lixisenatide, Lyxumia, Sanofi, adlyxin, approval, diabetes, type 2, type-2, zealand

Sanofi has announced that the US Food and Drug Administration (FDA) has approved Adlyxin (lixisenatide), which is a once-daily mealtime …
johnnolech

John Lechleiter to step down as Lilly CEO

July 27, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, John Lechleiter

Eli Lilly has announced that CEO John Lechleiter is set to retire, with David Ricks to assume the role as …

Shire and BMS secure NICE recommendations for oncology drugs

July 27, 2016 Research and Development, Sales and Marketing BMS, Baxalta, NICE, Oncaspar, Shire, Yervoy, opdivo

The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Shire’s Oncaspar (pegaspargase) and Bristol-Myers Squibb’s …

Pharma unit helps boost profits at Bayer

July 27, 2016 Research and Development, Sales and Marketing Bayer, Q2, results

The pharmaceutical division at Bayer was the driving force, as the company announced a 5.7% increase in second quarter profit …
headquarters_2_web

Eli Lilly Q2 2016 results surpass estimates

July 27, 2016 Research and Development, Sales and Marketing Eli Lilly, financial report

Eli Lilly has released its financial report for the second quarter of 2016, noting a number of promising results.  The …
cq5dam

New drugs to utilise DNA damage response to kill cancer cells

July 26, 2016 Research and Development, Sales and Marketing AstraZeneca, Cancer, Wellcome Trust, chemotherapy, dna damage response, university of sussex

The University of Sussex is set to produce a portfolio of new cancer drugs which exploit our DNA damage response …

BMS names Fouad Namouni as new oncology development head

July 26, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Erbitux, Fouad Namouni, Taxol, Yervoy, appointment, opdivo

Bristol-Myers Squibb has announced the appointment of Fouad Namouni to the position of oncology development head, effective July 25, 2016. …
The Gateway to Local Adoption Series

Latest content